NEW YORK, April 19, 2021 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a number one developer of mobile therapies for neurodegenerative illnesses, introduced as we speak that the Firm will maintain a convention name to replace shareholders on monetary outcomes for the primary quarter ended March 31, 2021, and supply a company replace, at 8:00 a.m. Japanese Time on April 26, 2021.
BrainStorm’s Chief Govt Officer, Chaim Lebovits, will current a company replace after which participant questions shall be answered. Becoming a member of Mr. Lebovits to reply funding neighborhood questions shall be Ralph Kern, MD, MHSc, President and Chief Medical Officer, Stacy Lindborg, PhD, Govt Vice President and World Head of Scientific Analysis, David Setboun, PharmD, MBA, Govt Vice President and Chief Working Officer, Preetam Shah, PhD, MBA, Govt Vice President and Chief Monetary Officer.
Contributors are inspired to submit their questions previous to the decision by sending them to: [email protected]. Questions must be submitted by 5:00 p.m. Japanese Time, Sunday, April 25, 2021.
The funding neighborhood might take part within the convention name by dialing the next numbers:
Participant Numbers:
Toll Free: 877-407-9205
Worldwide: 201-689-8054
Webcast URL: https://www.webcaster4.com/Webcast/Page/2354/40513
These eager about listening to the convention name reside through the web might achieve this by visiting the “Traders & Media” web page of BrainStorm’s web site at https://ir.brainstorm-cell.com/overview and clicking on the convention name hyperlink.
People who want to take heed to the replay of the convention name can achieve this by dialing the numbers under. The replay shall be out there for 14 days.
Replay Numbers:
Toll Free: 877-481-4010
Worldwide: 919-882-2331
Replay Passcode: 40513
About NurOwn®
The NurOwn® expertise platform (autologous MSC-NTF cells) represents a promising investigational therapeutic method to focusing on illness pathways necessary in neurodegenerative issues. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) which have been expanded and differentiated ex vivo. MSCs are transformed into MSC-NTF cells by rising them beneath patented circumstances that induce the cells to secrete excessive ranges of neurotrophic elements (NTFs). Autologous MSC-NTF cells are designed to successfully ship a number of NTFs and immunomodulatory cytokines on to the location of harm to elicit a desired organic impact and finally sluggish or stabilize illness development.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a number one developer of progressive autologous grownup stem cell therapeutics for debilitating neurodegenerative illnesses. The Firm holds the rights to scientific improvement and commercialization of the NurOwn® expertise platform used to supply autologous MSC-NTF cells via an unique, worldwide licensing settlement. Autologous MSC-NTF cells have acquired Orphan Drug designation standing from the U.S. Meals and Drug Administration (FDA) and the European Medicines Company (EMA) for the remedy of amyotrophic lateral sclerosis (ALS). BrainStorm has accomplished a Section three pivotal trial in ALS (NCT03280056); this trial investigated the protection and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Drugs (CIRM CLIN2-0989). BrainStorm accomplished beneath an investigational new drug utility a Section 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive a number of sclerosis (MS).
For extra info, go to the corporate’s web site at www.brainstorm-cell.com.
Contacts
Investor Relations:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Telephone: +1 646-465-1138
[email protected]
Media:
Paul Tyahla
SmithSolve
Telephone: + 1 973-713-3768
[email protected]
SOURCE Brainstorm Cell Therapeutics Inc
